Trifluoperazine-loaded leciplexes as potential nasal delivery systems for treatment of depression | ||||
| Azhar International Journal of Pharmaceutical and Medical Sciences | ||||
| Article 8, Volume 2, Issue 2, June 2022, Page 70-82 PDF (651.48 K) | ||||
| Document Type: Original research articles | ||||
| DOI: 10.21608/aijpms.2022.117220.1108 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Hanan Refai1; Dina A Osman2; Maha kA Khalifa   2; Soha Elsalhy1
| ||||
| 1Department of Pharmaceutics, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, Giza, Egypt | ||||
| 2Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt | ||||
| Abstract | ||||
| Trifluoperaizne (TFP) is an antipsychotic medication with limited oral bioavailability due to extensive first-pass metabolism; consequently, the goal of this project was to develop Leciplex nanoparticles for intranasal administration to circumvent oral issues. Leciplex NPs were formulated and optimized using the 21 31 full factorial statistical design. The formulae were characterized regarding their particle size (PS), polydispersity index (PDI), zeta potential (ZP), entrapment efficiency percentages (EE %), and the amount of drug released after 6 hours (Q6h). Optimized formula was selected based on the multilevel categoric model and contained DDAB as SAA and had a PL-90G:SAA ratio of 1:1. It was showed a PS of 174.79 nm, a PDI of 0.241, a ZP of 38.21 mV, an EE% of 53.59 % and a Q6h of 65.58 %. Thus, it can be inferred that the developed Leciplex could effectively be explored as a promising nasal delivery of TFP in the effective treatment of depression. | ||||
| Keywords | ||||
| Trifluoperazine hydrochloride; Leciplex; factorial design; nasal drug delivery; depression | ||||
|
Statistics Article View: 398 PDF Download: 455 |
||||
